Prescribing information (external link)
Different by design
KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1
For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).
KESIMPTA is the first fully human B-cell targeting monoclonal antibody in multiple sclerosis (MS)1,2
Watch the video below to learn how KESIMPTA works to preferentially target and deplete B-cells in the lymph nodes whilst sparing B-cells in the spleen.1,3,4
VIDEO
Learn more about the mechanism of action of KESIMPTA
MS, multiple sclerosis; RMS, relapsing forms of multiple sclerosis; SmPC, summary of product characteristics.
References
KESIMPTA (ofatumumab) Summary of Product Characteristics.
Hauser SL, et al. Neurol Ther 2023;12(5):1491–1515.
Torres JB, et al. Front Immunol 2022;13:814064.
Huck C, et al. J Neuroimmune Pharmacol 2019;14(4):709–719.
UK | January 2026 | FA-11583616
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
